Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Aandelenkoers, Nieuws & Analyse

DPHL Overzicht aandelen

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Meer informatie

DPHL fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 62.48% per jaar groeien

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Dechra Pharmaceuticals PLC Concurrenten

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Dechra Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	UK£38.70
52 Week Hoogtepunt	UK£38.84
52 Week Laag	UK£24.74
Bèta	0.78
11 maand verandering	0.55%
3 maanden verandering	2.27%
1 Jaar Verandering	35.79%
33 jaar verandering	5.91%
5 jaar verandering	63.71%
Verandering sinds IPO	744.98%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	DPHL	GB Pharmaceuticals	GB Markt
7D	0.2%	4.5%	2.2%
1Y	35.8%	0.7%	8.0%

Rendement versus industrie: DPHL overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement 0.7 % opleverde.

Rendement versus markt: DPHL overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 8 %.

Prijsvolatiliteit

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: DPHL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van DPHL is het afgelopen jaar gedaald van 6% naar 1%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Samenvatting

Hoe verhouden de winst en inkomsten van Dechra Pharmaceuticals zich tot de beurswaarde?
DPHL fundamentele statistieken
Marktkapitalisatie	UK£4.40b
Inkomsten(TTM)	-UK£27.90m
Inkomsten(TTM)	UK£761.50m

5.8x

P/S-verhouding

-157.8x

Koers/Winstverhouding

Is DPHL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DPHL resultatenrekening (TTM)
Inkomsten	UK£761.50m
Kosten van inkomsten	UK£331.90m
Brutowinst	UK£429.60m
Overige uitgaven	UK£457.50m
Inkomsten	-UK£27.90m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.24
Brutomarge	56.42%
Nettowinstmarge	-3.66%
Schuld/Eigen Vermogen Verhouding	64.6%

Hoe presteerde DPHL op de lange termijn?

Bekijk historische prestaties en vergelijking

DPHL Overzicht aandelen

Beloningen

Risicoanalyse

Dechra Pharmaceuticals PLC Concurrenten

LSE:HIK

UK£4.3b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Dechra Pharmaceuticals PLC Samenvatting

5.8x

-157.8x

Inkomsten en omzet